Related Experiment Video
Updated: Apr 6, 2026

Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
Published on: June 28, 2021
Soluble CD163 is increased in patients with acute pancreatitis independent of disease severity
Thomas Karrasch1, Tanja Brünnler1, Okka W Hamer2
1Department of Internal Medicine I, Regensburg University Hospital, Regensburg, Germany.
Abstract:
Macrophages are crucially involved in the pathophysiology of acute pancreatitis. Soluble CD163 (sCD163) is specifically released from macrophages and systemic levels are increased in inflammatory diseases. Here, sCD163 was measured in serum of 50 patients with acute pancreatitis to find out possible associations with disease activity. Admission levels of systemic sCD163 were nearly three-fold higher in patients with acute pancreatitis compared to controls. In patients sCD163 did not correlate with C-reactive protein and leukocyte count as established markers of inflammation. Levels were not associated with disease severity assessed by the Schroeder score, Balthazar score, Acute Physiology, Age, and Chronic Health Evaluation (Apache) II score and peripancreatic necrosis score. Soluble CD163 was not related to complications of acute pancreatitis. These data show that serum sCD163 is increased in acute pancreatitis indicating activation of macrophages but is not associated with disease severity and outcome.
Insights
Serum soluble CD163 (sCD163) is elevated in acute pancreatitis, indicating macrophage activation. However, sCD163 levels did not correlate with inflammation markers, disease severity, or complications in patients.
Area of Science:
- Immunology
- Gastroenterology
- Biochemistry
Background:
- Macrophages play a key role in acute pancreatitis pathogenesis.
- Soluble CD163 (sCD163), a macrophage-specific marker, is elevated in inflammatory conditions.
Purpose of the Study:
- To investigate the association between serum sCD163 levels and disease activity in acute pancreatitis.
- To determine if sCD163 correlates with inflammation markers, disease severity, or complications.
Main Methods:
- Serum sCD163 was measured in 50 acute pancreatitis patients and controls.
- Disease severity was assessed using Schroeder, Balthazar, Apache II, and peripancreatic necrosis scores.
- Correlation with C-reactive protein and leukocyte count was analyzed.
Main Results:
- Admission sCD163 levels were significantly higher (nearly three-fold) in acute pancreatitis patients versus controls.
- sCD163 did not correlate with C-reactive protein or leukocyte count.
- No association was found between sCD163 levels and disease severity scores or complications.
Conclusions:
- Elevated serum sCD163 in acute pancreatitis reflects macrophage activation.
- sCD163 is not a reliable biomarker for predicting disease severity or outcome in acute pancreatitis.
More Related Videos
07:38Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
07:10Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Chronic Pancreatitis II: Collaborative Care
Assessment: